Moleculin Biotech (Nasdaq: MBRX) announced a 1-for-20 reverse stock split that will take effect at 12:01 a.m. ET on October 20, 2026. The split will reduce outstanding shares to roughly 1.05 million and the stock will resume trading on the Nasdaq Capital Market under the same ticker with a new CUSIP.
Moleculin Biotech, Inc. (Nasdaq: MBRX) filed an amendment to its amended and restated certificate of incorporation with the Delaware Secretary of State to implement a 1-for-20 reverse stock split of its common stock. The split is scheduled to become effective at 12:01 a.m. Eastern Time on October 20, 2026, and the company’s shares will reopen for trading on the Nasdaq Capital Market that same day under the existing ticker symbol but with a new CUSIP number 60855D 507 (source 1).
Under the terms of the split, every twenty pre‑split shares will be consolidated into one post‑split share, with the nominal par value remaining at $0.001 per share. No fractional shares will be issued; shareholders who would otherwise receive a fractional share will instead receive a cash payment in lieu of that fraction (source 1).
The transaction will reduce Moleculin’s outstanding share count from approximately 20.9 million to about 1.05 million, while the authorized share pool stays at 500 million. This reduction is intended to improve the market perception of the stock and bring the share price into a range more attractive to institutional investors (source 1).
Beyond the corporate action, Moleculin remains focused on advancing its late‑stage oncology pipeline. Its lead candidate, Annamycin, is being evaluated in the pivotal MIRACLE (MB‑108) Phase 2/3 trial for relapsed or refractory acute myeloid leukemia, building on encouraging Phase 1B/2 data (source 1). The company is also developing WP1066, an immune‑modulator targeting brain tumors and pancreatic cancer, and WP1122, a potential antiviral antimetabolite (source 1).
Analysts will watch the post‑split trading dynamics and the progress of the MIRACLE trial as key indicators of Moleculin’s valuation trajectory. The reverse split, combined with ongoing clinical milestones, aims to position the company for broader market participation and potential future financing opportunities (source 1).